We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Experts have said the ongoing government shutdown may already have delayed approval and launch of new drugs, as the FDA’s spare cash reserves dwindle with every day that the impasse continues.